Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 471871202 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Velan Capital Investment Management LP
13G
|
9.9% |
8/17/2026
Event 8/17/2026
|
|
| Velan Capital Master Fund LP | 8.9% | ||
| Velan Capital Holdings LLC | 8.9% | ||
| Velan Horizon Fund LP | 0.2% | ||
| Velan Horizon GP LLC | 0.2% | ||
| Avego Healthcare Capital, L.P. | 0.7% | ||
| Avego Healthcare Capital Holdings, LLC | 0.7% | ||
| Avego Management LLC | 0.7% | ||
| Velan Capital Investment Management LP | 9.9% | ||
| Velan Capital Management LLC | 9.9% | ||
| Morgan Adam | 9.9% | ||
| Venkataraman Balaji | 9.9% | ||
| Kapoor Vishal | 0.1% | ||
|
Velan Capital Investment Management LP
13D/A
Amendment 3
|
9.9% |
7/20/2026
Event 7/16/2026
|
|
| Velan Capital Master Fund LP | 8.9% | ||
| Velan Capital Holdings LLC | 8.9% | ||
| Velan Horizon Fund LP | 0.2% | ||
| Velan Horizon GP LLC | 0.2% | ||
| Avego Healthcare Capital, L.P. | 0.7% | ||
| Avego Healthcare Capital Holdings, LLC | 0.7% | ||
| Avego Management LLC | 0.7% | ||
| Velan Capital Investment Management LP | 9.9% | ||
| Velan Capital Management LLC | 9.9% | ||
| Morgan Adam | 9.9% | ||
| Venkataraman Balaji | 9.9% | ||
| Kapoor Vishal | 0.1% | ||
|
Integrated Core Strategies (US) LLC
13G/A
Amendment 1
|
1.7% |
7/10/2026
Event 6/30/2026
|
|
| Integrated Core Strategies (US) LLC | 1.7% | ||
| Millennium Management LLC | 1.7% | ||
| Millennium Group Management LLC | 1.7% | ||
| Israel A. Englander | 1.7% | ||
|
Morgan Stanley
13G/A
Amendment 1
|
4.8% |
5/12/2026
Event 3/31/2026
|
|
| Morgan Stanley | 4.8% | ||
| Morgan Stanley Capital Services LLC | 4.6% | ||
|
Soleus Capital Master Fund, L.P.
13G/A
Amendment 4
|
1.0% |
5/8/2026
Event 3/31/2026
|
|
| Soleus Capital Master Fund, L.P. | 0.4% | ||
| Soleus Private Equity Fund III, L.P. | 0.6% | ||
| Soleus Private Equity GP III, LLC | 0.6% | ||
| Soleus PE GP III, LLC | 0.6% | ||
| Soleus Capital, LLC | 0.4% | ||
| Soleus Capital Group, LLC | 0.4% | ||
| Soleus Capital Management, L.P. | 1.0% | ||
| Soleus GP, LLC | 1.0% | ||
| Guy Levy | 1.0% | ||
|
Goldman Sachs Group Inc
13G/A
Amendment 1
|
0.5% |
5/8/2026
Event 3/31/2026
|
|
| The Goldman Sachs Group, Inc. | 0.5% | ||
| Goldman Sachs & Co. LLC | 0.5% | ||
|
Integrated Core Strategies (US) LLC
13G
|
5.8% |
2/25/2026
Event 2/18/2026
|
|
| Integrated Core Strategies (US) LLC | 5.8% | ||
| Millennium Management LLC | 5.8% | ||
| Millennium Group Management LLC | 5.8% | ||
| Israel A. Englander | 5.8% | ||
|
Carlyle Group Inc.
13D/A
Amendment 4
|
3.8% |
2/18/2026
Event 2/18/2026
|
|
| The Carlyle Group Inc. | 3.8% | ||
| Carlyle Holdings I GP Inc. | 3.8% | ||
| Carlyle Holdings I GP Sub L.L.C. | 3.8% | ||
| Carlyle Holdings I L.P. | 3.8% | ||
| CG Subsidiary Holdings L.L.C. | 3.8% | ||
| TC Group, L.L.C. | 3.8% | ||
| Carlyle Investment Management L.L.C. | 3.8% | ||
| Carlyle Genesis UK LLC | 3.8% | ||
| Abingworth LLP | 3.8% | ||
| Abingworth Bioventures VII LP | 3.8% | ||
|
Goldman Sachs Group Inc
13G
|
6.3% |
2/12/2026
Event 12/31/2025
|
|
| The Goldman Sachs Group, Inc. | 6.3% | ||
| Goldman Sachs & Co. LLC | 6.3% | ||
|
Morgan Stanley
13G
|
7.0% |
2/11/2026
Event 12/31/2025
|
|
| Morgan Stanley | 7.0% | ||
| Morgan Stanley Capital Services LLC | 6.8% | ||
|
Acorn Bioventures, L.P.
13G/A
Amendment 1
|
5.3% |
1/26/2026
Event 1/23/2026
|
|
| Acorn Bioventures, L.P. | 2.2% | ||
| Acorn Capital Advisors GP, LLC | 2.2% | ||
| Acorn Bioventures 2, L.P. | 3.1% | ||
| Acorn Capital Advisors GP 2, LLC | 3.1% | ||
| Anders Hove | 5.3% | ||
|
Acorn Bioventures, L.P.
13G
|
6.4% |
12/2/2025
Event 12/1/2025
|
|
| Acorn Bioventures, L.P. | 2.7% | ||
| Acorn Capital Advisors GP, LLC | 2.7% | ||
| Acorn Bioventures 2, L.P. | 3.7% | ||
| Acorn Capital Advisors GP 2, LLC | 3.7% | ||
| Anders Hove | 6.4% | ||
| T. Rowe Price Investment Management, Inc. 13G | 7.1% |
11/14/2025
Event 9/30/2025
|
|
|
Qiming U.S. Healthcare Fund II, L.P.
13G/A
Amendment 2
|
3.3% |
11/14/2025
Event 9/30/2025
|
|
| Qiming U.S. Healthcare Fund II, L.P. | 3.3% | ||
| Qiming U.S. Healthcare GP II, LLC | 3.3% | ||
| Mark McDade | 3.3% | ||
| Gary E Rieschel | 3.3% | ||
|
Kingdon Capital Management, L.L.C.
13G/A
Amendment 1
|
4.7% |
11/12/2025
Event 9/30/2025
|
|
| Kingdon Capital Management, L.L.C. | 4.7% | ||
| Mark Kingdon | 4.7% | ||
| Morgan Stanley 13G/A Amendment 1 | 2.8% |
11/7/2025
Event 9/30/2025
|
|
|
Velan Capital Investment Management LP
13D/A
Amendment 2
|
9.6% |
9/23/2025
Event 9/19/2025
|
|
| Velan Capital Master Fund LP | 8.5% | ||
| Velan Capital Holdings LLC | 8.5% | ||
| Velan Horizon Fund LP | 0.1% | ||
| Velan Horizon GP LLC | 0.1% | ||
| Avego Healthcare Capital, L.P. | 0.9% | ||
| Avego Healthcare Capital Holdings, LLC | 0.9% | ||
| Avego Management LLC | 0.9% | ||
| Velan Capital Investment Management LP | 9.6% | ||
| Velan Capital Management LLC | 9.6% | ||
| Morgan Adam | 9.6% | ||
| Venkataraman Balaji | 9.6% | ||
| Kapoor Vishal | 0.1% | ||
| Morgan Stanley 13G | 5.0% |
8/6/2025
Event 6/30/2025
|
|
| BlackRock, Inc. 13G/A Amendment 1 | 1.5% |
7/17/2025
Event 6/30/2025
|
|
|
Kingdon Capital Management, L.L.C.
13G
|
5.1% |
7/11/2025
Event 7/3/2025
|
|
| Kingdon Capital Management, L.L.C. | 5.1% | ||
| Mark Kingdon | 5.1% | ||
|
Soleus Capital Master Fund, L.P.
13G/A
Amendment 3
|
10.0% |
2/11/2025
Event 12/31/2024
|
|
| Soleus Private Equity Fund III, L.P. | 1.3% | ||
| Soleus Private Equity GP III, LLC | 1.3% | ||
| Soleus PE GP III, LLC | 1.3% | ||
| Soleus Capital Master Fund, L.P. | 8.6% | ||
| Soleus Capital, LLC | 8.6% | ||
| Soleus Capital Group, LLC | 8.6% | ||
| Soleus Capital Management, L.P. | 10.0% | ||
| Soleus GP LLC | 10.0% | ||
| Guy Levy | 10.0% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q2 | 49 | 12.0 M | $5.05 M |
| 2026 Q1 | 61 | 15.8 M | $13.9 M |
| 2025 Q4 | 61 | 19.6 M | $35.9 M |
| 2025 Q3 | 65 | 20.2 M | $47.8 M |
| 2025 Q2 | 70 | 12.5 M | $69.6 M |
| 2025 Q1 | 73 | 13.0 M | $56.1 M |
| 2024 Q4 | 99 | 15.7 M | $335 M |
| 2024 Q3 | 89 | 14.7 M | $275 M |
| 2024 Q2 | 76 | 14.9 M | $337 M |
| 2024 Q1 | 69 | 13.4 M | $391 M |
| 2023 Q4 | 1 | 495 k | $390 k |